Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

NCT00529243 ·Status: COMPLETED ·Phase: PHASE3

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

NCT01480713 ·Status: COMPLETED ·Phase: PHASE3

Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients

NCT02210715 ·Status: COMPLETED ·Phase: PHASE4

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

NCT01231685 ·Status: COMPLETED ·Phase: PHASE2

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

NCT03195452 ·Status: COMPLETED ·Phase: PHASE2

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

NCT02247687 ·Status: TERMINATED ·Phase: PHASE3

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

NCT01245101 ·Status: TERMINATED ·Phase: PHASE4

Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

NCT00454337 ·Status: COMPLETED ·Phase: PHASE3

Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

NCT01048671 ·Status: COMPLETED

Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults

NCT02218320 ·Status: COMPLETED

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029 ·Status: TERMINATED ·Phase: PHASE3

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827 ·Status: COMPLETED ·Phase: PHASE2

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

NCT01533259 ·Status: COMPLETED ·Phase: PHASE3

BRAVO: Background Regimen of Raltegravir on Virologic Outcome

NCT00751530 ·Status: COMPLETED

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

NCT02097108 ·Status: COMPLETED ·Phase: PHASE2

Observational Data Analysis in EuroSIDA (MK-0518-058)

NCT01078233 ·Status: COMPLETED

Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan

NCT01467349 ·Status: COMPLETED

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433 ·Status: COMPLETED ·Phase: PHASE1

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

NCT01814722 ·Status: TERMINATED

Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery

NCT00562510 ·Status: TERMINATED ·Phase: PHASE3

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

NCT00709397 ·Status: TERMINATED

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746 ·Status: COMPLETED ·Phase: PHASE3

Pilot Study of Raltegravir Lipodystrophy IISP

NCT01164605 ·Status: UNKNOWN ·Phase: NA

Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients

NCT01190124 ·Status: COMPLETED

Renal Transplantation and Raltegravir in HIV-Infected Patients

NCT01453192 ·Status: COMPLETED ·Phase: PHASE3